FDA Approval of Tonmya: Tonmya, a new non-opioid therapy for fibromyalgia, has been approved by the FDA, marking the first new treatment for this chronic pain condition in over 15 years. It is designed for rapid absorption and has shown significant efficacy in reducing pain in clinical trials.
Impact on Fibromyalgia Patients: The approval of Tonmya offers renewed hope to the over 10 million adults in the U.S. suffering from fibromyalgia, particularly women, who have long awaited innovative treatment options to alleviate their debilitating symptoms.
TNXP
$18.6+Infinity%1D
Analyst Views on TNXP
About TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
